Article Text

Download PDFPDF
Correction: management of prostatic carcinoma (3 November 1986, p87)


We stated that aminoglutethimide, which has been considered as an alternative to adrenalectomy in metastatic carcinoma of the prostate, reduces adrenal production of androgen and cortisol. There is evidence that this is not so, and that aminoglutethimide given alone raises adrenal androgen production.1 In almost all published work on its use in prostatic cancer aminoglutethimide has been given with a glucocorticoid, and it is evidently the glucocorticoid which suppresses adrenal androgen production.2 It is not clear therefore whether the use of aminoglutethimide with hydrocortisone offers any advantage over that of hydrocortisone alone.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.